Search tips
Search criteria

Results 1-16 (16)

Clipboard (0)
Year of Publication
Document Types
1.  Alternative Screening Approaches for Discovery of Middle East Respiratory Syndrome Coronavirus Inhibitors 
Two coronaviruses causing severe respiratory disease and high mortality rates emerging within the past dozen years reinforces the need for clinically efficacious antivirals targeting coronaviruses. Alternative screening approaches for antivirals against the recently emergent Middle East respiratory syndrome coronavirus (MERS-CoV) may provide lead compounds to address this need. Two Antimicrobial Agents and Chemotherapy (AAC) papers screened libraries of approved compounds that may potentially be repurposed as MERS-CoV antivirals. A third AAC paper showed that a previously described severe acute respiratory syndrome coronavirus (SARS-CoV) helicase inhibitor also has activity against MERS-CoV.
PMCID: PMC4135998  PMID: 24867994
2.  Eight More Ways To Deal with Antibiotic Resistance 
The fight against antibiotic resistance must be strengthened. We propose actions that U.S. government agencies and private sector entities can take to build a more comprehensive effort. These actions can increase the viability of investing in new antibiotics, ensure the quality and stewardship of all antibiotics, and make responses to emerging resistance more informed. Success requires the thoughtful exercise of federal authority and a firm commitment to share data and reward developers for the value generated with new, life-saving antibiotics.
PMCID: PMC4136015  PMID: 24867992
3.  Towards a Paradigm Shift in the Treatment of Chronic Chagas Disease 
Treatment for Chagas disease with currently available medications is recommended universally only for acute cases (all ages) and for children up to 14 years old. The World Health Organization, however, also recommends specific antiparasite treatment for all chronic-phase Trypanosoma cruzi-infected individuals, even though in current medical practice this remains controversial, and most physicians only prescribe palliative treatment for adult Chagas patients with dilated cardiomyopathy. The present opinion, prepared by members of the NHEPACHA network (Nuevas Herramientas para el Diagnóstico y la Evaluación del Paciente con Enfermedad de Chagas/New Tools for the Diagnosis and Evaluation of Chagas Disease Patients), reviews the paradigm shift based on clinical and immunological evidence and argues in favor of antiparasitic treatment for all chronic patients. We review the tools needed to monitor therapeutic efficacy and the potential criteria for evaluation of treatment efficacy beyond parasitological cure. Etiological treatment should now be mandatory for all adult chronic Chagas disease patients.
PMCID: PMC3910900  PMID: 24247135
4.  The FDA Reboot of Antibiotic Development 
Antimicrobial Agents and Chemotherapy  2013;57(10):4605-4607.
PMCID: PMC3811409  PMID: 23896479
7.  Reflections on the Approach to Treatment of a Mycologic Disaster 
PMCID: PMC3623368  PMID: 23384533
9.  Early Endpoints for Acute Bacterial Skin and Skin Structure Infections 
PMCID: PMC3346651  PMID: 22314521
11.  Resistance to Chloroquine Unhinges Vivax Malaria Therapeutics▿† 
PMCID: PMC3088196  PMID: 21383088
12.  Critical Annotations to the Use of Azole Antifungals for Plant Protection 
Antimicrobial Agents and Chemotherapy  2001;45(11):2987-2990.
PMCID: PMC90772  PMID: 11600346
13.  Autolysis Control Hypotheses for Tolerance to Wall Antibiotics† 
Antimicrobial Agents and Chemotherapy  2001;45(10):2671-2675.
PMCID: PMC90715  PMID: 11557453
14.  Search for New Drugs for Treatment of Tuberculosis 
PMCID: PMC90582  PMID: 11408205
16.  Reconsidering Some Approved Antimicrobial Agents for Tuberculosis▿  
Antimicrobial Agents and Chemotherapy  2009;53(11):4577-4579.
PMCID: PMC2772312  PMID: 19738008

Results 1-16 (16)